Guardion Health Sciences, Inc. (NASDAQ:GHSI) Short Interest Down 42.7% in August

Guardion Health Sciences, Inc. (NASDAQ:GHSI) was the target of a significant decline in short interest during the month of August. As of August 31st, there was short interest totalling 196,400 shares, a decline of 42.7% from the August 15th total of 342,900 shares. Based on an average daily volume of 306,600 shares, the short-interest ratio is currently 0.6 days.

GHSI stock remained flat at $$1.22 during midday trading on Friday. The company’s stock had a trading volume of 197,599 shares, compared to its average volume of 2,062,387. The company’s 50-day moving average is $1.32 and its 200-day moving average is $1.72. Guardion Health Sciences has a twelve month low of $0.99 and a twelve month high of $8.40. The stock has a market cap of $29.80 million, a PE ratio of -1.82 and a beta of 0.05.

Guardion Health Sciences (NASDAQ:GHSI) last posted its quarterly earnings data on Monday, August 16th. The company reported ($0.10) earnings per share for the quarter. Guardion Health Sciences had a negative return on equity of 41.67% and a negative net margin of 666.39%. The business had revenue of $1.22 million during the quarter.

A number of hedge funds have recently bought and sold shares of GHSI. BlackRock Inc. purchased a new position in Guardion Health Sciences in the first quarter worth $1,505,000. Vanguard Group Inc. lifted its position in shares of Guardion Health Sciences by 83.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,069,815 shares of the company’s stock valued at $1,883,000 after buying an additional 485,870 shares during the last quarter. Morgan Stanley lifted its position in shares of Guardion Health Sciences by 2,326.1% during the 2nd quarter. Morgan Stanley now owns 326,987 shares of the company’s stock valued at $575,000 after buying an additional 313,509 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Guardion Health Sciences during the 1st quarter valued at $666,000. Finally, State Street Corp purchased a new position in shares of Guardion Health Sciences during the 2nd quarter valued at $231,000. 10.21% of the stock is currently owned by institutional investors and hedge funds.

Guardion Health Sciences Company Profile

Guardion Health Sciences, Incis a clinical nutrition and diagnostics company, which develops medical foods and medical devices in the ocular health space and develops nutraceutical products to provide supportive health benefits to consumers. The firm operates through the following segments Medical Foods and Nutraceuticals & Medical Devices.

Featured Article: Growth and Income Funds

Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.